Latest bladder cancer Stories

WINSTON-SALEM, N.C., Jan. 30, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced advances for its two lead programs, the Neo-Urinary Conduit(TM) and Neo-Kidney Augment(TM). "We look forward to successfully implanting the remaining three patients in the ongoing Phase 1 trial for the Neo-Urinary Conduit by the end of this quarter. Following the implantation of patient seven, we have begun to transfer the surgical procedure to...

The US Drug Watchdog says, "Actos users who developed bladder cancer have incredibly horrific stories, many lives have been destroyed, and we fear many lives have been lost, and most diabetics have never heard of the correlation between the diabetes drug called Actos, and a elevated risk of bladder cancer, but we have, and we are doing everything possible to get the word out to victims, or their family members." The US Drug Watchdog is now urging all Actos users, who now have...

Bernstein Liebhard LLP is currently investigating Actos lawsuits on behalf of individuals who developed bladder cancer following long-term use of the type 2 diabetes medication. New York, New York (PRWEB) January 20, 2013 Actos bladder cancer lawsuits continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Western District of Louisiana, Bernstein Liebhard LLP reports. The next Status Conference in the Actos litigation has been scheduled for...

The US Drug Watchdog says,"We fear most of diabetics in the US, who took the diabetes drug called Actos, would never make the mental connection between their bladder cancer, and their use of the diabetes drug called Actos, so we are asking family members, and we are urging loved ones, or friends to help us out." If a family member, or friend was a diabetic, was using the diabetes drug called Actos, and developed bladder cancer the US Drug Watchdog is urging the family members to...

Smoking not only causes bladder cancer—it also affects its course, in that people who smoke more have greater likelihood of developing more aggressive and deadly disease. That is one of the conclusions of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The study also found that a panel of bladder cancer markers can predict which particular cases are at the highest risk for a fatal outcome. Researchers have known that smoking is one of...

PASADENA, Calif., Jan. 9, 2013 /PRNewswire/ -- The presence of microscopic hematuria - blood found in urine that can't be seen by the naked eye -- does not necessarily indicate the presence of cancer, according to a Kaiser Permanente Southern California study published in the journal Mayo Clinic Proceedings. The study suggests that tests routinely done on patients with this condition could be avoided and has led to the creation of a screening tool to better diagnose certain types...

Diagnostic pathology firm to offer breakthrough prostate cancer assay to urology market THUNDER BAY, ON, Jan. 7, 2013 /PRNewswire/ - Mitomics, a developer of mitochondrial DNA-based tests for early disease detection, today announced it has entered into a sales and marketing agreement for the Prostate Core Mitomic Test((TM)) (PCMT(TM)) with Sterling Pathology National Laboratories. Under the agreement, Sterling Pathology National Laboratories, a leader in diagnostic pathology...

BELLEVILLE, ON, Jan. 3, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on the return of global rights to Urocidin(TM) from Endo Pharmaceuticals (Endo), a subsidiary of Endo Health Solutions. It was announced on December 21, 2012 that the two companies came to an agreement that a mutually favourable path forward for the product is to return its global rights to...

-Bioniche identifies potential for early access to the Canadian market- BELLEVILLE, ON, Dec. 21, 2012 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that global rights to Urocidin(TM) are being returned to the Company from Endo Pharmaceuticals (Endo), a subsidiary of Endo Health Solutions. On November 5(th), it was announced that a second Phase III clinical trial with...

WINSTON-SALEM, N.C., Dec. 21, 2012 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that Scott D. Flora, President & Chief Executive Officer at OmniGuide, has resigned from Tengion's Board of Directors, effective December 19, 2012. "Scott has been a valuable asset to Tengion and his expertise in the medical and surgical device arenas has been an excellent resource for the Company over the last year," reflected David Scheer, Chairman...